论文部分内容阅读
罗氏(Roche)和葛兰素史克(GSK)制药公司日前宣布,首种静脉注射剂型 Boniva 药物(Iban-dronate sodium)获得美国食品药品管理局(FDA)批准用以治疗绝经后骨质疏松症。Boniva 注射制剂作为骨质疏松症最常用的处方药——二磷酸盐类药物可首次按季度给药治疗绝经后的骨质疏松症患者,医保人员只需每3个月给予患者注射1次 Boniva 治疗即可。美国内布拉斯加州奥马哈 Creighton 大学骨质疏松症研究中心的 Boniva 注射剂临床试验主任、骨质疏松症首席专家 Robert R.Recker 博士报道指出,Boniva 注射剂的应用是一种独特而新颖的骨质疏松症疗法,它可为更多妇女强骨治疗带来益处,特别是对那些二磷酸盐化合物口服制剂治疗困难者。给予口服二磷酸盐化合物治疗困难者15～30秒
Roche and GSK Pharmaceuticals Inc. announced that the first intravenous injection of Iban-dronate sodium has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of postmenopausal osteoporosis. Boniva Injection is the most commonly prescribed prescription for osteoporosis - diphosphates are available for the first time on a quarterly basis for the treatment of postmenopausal osteoporosis patients who need to be given Boniva once every 3 months Can be. Dr. Robert R. Recker, chief clinical trial on injectable injectables at the Creighton University Osteoporosis Research Center in Omaha, Nebraska, reported that Boniva injection is a unique and novel bone It is a remedy for osteoporosis that can benefit more women in intensive bone therapies, especially those who are refractory to oral diphosphate formulations. Oral diphosphate compounds given to treatment difficulties 15 to 30 seconds